SNDLの空売り状況は、投資家がSNDLの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

SNDL (NASDAQ:SNDL) 株価情報, 空売り情報

SNDL

SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.

SNDL Inc

Biotech

News

General

ARCT

Arcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial

Current Co-Chairman of the Board will now also serve as Chief Executive Officer
Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation&#x2122; (nano-PFA or nsPFA&#x2122;) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.

Management

PLSE

Pulse Biosciences Appoints Paul LaViolette As Chief Executive Officer

TYRA

Tyra Biosciences Receives IND Clearance From The FDA To Proceed With A Phase 2 Study Of TYRA-300 In Non-Muscle Invasive Bladder Cancer

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $11 price target.

Price Target

Reiteration

Analyst Ratings

KMDA

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

Contracts

Nano Labs Subsidiary Nano Bit, BitFi Enter Strategic Partnership; Terms Not Disclosed

RVTY

Revvity Receives FDA Clearance For EUROIMMUN's Free Testosterone Test

TLSA

Tiziana Life Sciences Announced Findings On Benefits Of Its Nasal Anti-CD3 Monoclonal Antibody In Sustaining Tissue Homeostasis And Mitigating The Side Effects Associated With GLP-1 Agonists Discontinuation

<ul>
<li>Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025</li>
<li>Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified</li>
<li>Extending the cash runway to the start of 2027 by reducing costs, including an approximate 65% reduction in workforce and expected closure of the U.K. site</li>
<li>Future operations will be focused at the U.S. site in Germantown, Maryland</li>
</ul>
OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) ("Barinthus Bio," or the "Company"), today provided a strategic business and financial update. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease.

BRNS

Barinthus Bio Restructures, Prioritizes VTP-1000 For Celiac Disease With Phase 1 Data In Mid-2025, Pauses VTP-300 For Hepatitis B Pending Partner; Cuts 65% Workforce, Closes U.K. Site To Extend Cash To 2027 With $112M Reserves; Focuses U.S. Operations In Germantown

Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped over 40% in premarket after it announced a breakthrough in its True All-Solid-State <a href="https://www.benzinga.com/topic/batterie">Battery</a> (ASSB) technology. Technical analysis shows strong support for the stock performance.
What Happened: Unlike conventional batteries, Microvast&#8217;s ASSB eliminates liquid electrolytes, enabling high-voltage operation and simplifying system architecture.
&#8220;Our solid-state battery innovation represents a significant leap forward in addressing real-world safety and efficiency challenges,&#8221; stated CEO Yang Wu.
The press release lists the new battery&#8217;s key features, which include enhanced safety and efficiency along with bipolar stacking architecture, which helps achieve high voltages unattainable by liquid-based batteries. The proprietary all-solid electrolyte separator in the battery ensures conductivity and structural stability.
See Also:<a href="https://www.benzinga.com/25/01/42908280/intel-aims-for-cpu-market-share-growth-ai-breakthroughs-citi-reiterates-neutral-as-new-ceo-appointment-expected-in-coming-months"> Intel Stock Has Fallen Over 58% In 1 Year, But Citi Maintains &#8216;Neutral&#8217; Rating On Expected Replacement Of Pat Gelsinger In A &#8216;Couple Of Months&#8217; </a>
Why It Matters: Microvast&#8217;s ASSB technology is poised to transform various sectors according to the company. This technology will be helpful in data centers, electric vehicles, and advanced robotics, as it offers customized solutions with high energy density and improved safety.
Microvast was up 44.39% at $2.7 in premarket during the publication of this article. It ended 10.95% lower in Wednesday&#8217;s session. The shares have risen by a staggering 345.24% over the last six months and 61.21% over the last year. Nasdaq Composite underperformed the stock as it rose 4.46% in the last six months and 30.1% over the last year.
Technical analysis of daily moving averages with the help of <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> shows strong support for the stock in both the near and long term.
Mirovast&#8217;s shares in premarket trade were above its eight-day simple moving average of $2.29 and its 20-day average of $1.87 apiece, showing strong support in the near term.
The 50 and 200-day simple moving averages were also below the share price at $1.13 and $0.57, respectively, suggesting a bullish uptrend.
On the other hand, the relative strength index of 62.97 suggested that the stock could be moderately overbought but still in the neutral zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1024x576.png" alt="" class="wp-image-727887" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073956/MVST-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42893264/charlie-mungers-top-pick-costco-reports-strong-december-sales-analysts-expect-a-7-jump-in-january">Charlie Munger&#8217;s Top Pick Costco Reports Strong December Sales: Analysts Expect A 7% Jump In January</a> 
According to <a href="https://www.benzinga.com/quote/MVST/analyst-ratings">Benzinga</a>, MVST has a consensus price target of $4.4 per share based on the ratings of five analysts. The highest price target out of all the analysts tracked by Benzinga is $8 apiece issued by Cantor Fitzgerald as of Dec. 18. The lowest target price is $3 per share issued by HC Wainwright &amp; Co. on Nov. 18.
The average recent price target between HC Wainwright &amp; Co. and Janney Montgomery Scott implies a 24.22% upside for MVST.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/MVST/analyst-ratings"><img loading="lazy" decoding="async" width="945" height="355" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR.png" alt="" class="wp-image-727883" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR.png 945w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10073842/MVST-ANR-768x289.png 768w" sizes="(max-width: 945px) 100vw, 945px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42906089/california-wildfires-ignite-concerns-for-insurance-stocks-here-are-some-insurance-etfs-which-could-be-impacted">California Wildfires Ignite Concerns For Insurance Stocks: Here Are Some Insurance ETFs Which Could Be Impacted </a></li>
</ul>
Image courtesy of Microvast

Analyst Color

Equities

Market Summary

Technicals

Markets

Trading Ideas

MVST

Microvast's Breakthrough In All-Solid State Battery Tech Propels Shares To Over 40% In Premarket: Here's What Technical Analysis Says

TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) reported quarterly earnings of $3.09 per share which beat the analyst consensus estimate of $3.05 by 1.31 percent. The company reported quarterly sales of $15.845 billion which beat the analyst consensus estimate of $15.220 billion by 4.11 percent. This is a 9.98 percent increase over sales of $14.407 billion the same period last year.

Earnings

Earnings Beats

TD Synnex Q4 2024 Adj. EPS $3.09 Beats $3.05 Estimate, Sales $15.845B Beat $15.220B Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) with a Buy and maintains $38 price target.

PVLA

HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $38 Price Target

Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, DKK 1 nominal value (the "ADS ratio"), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the "ADS ratio change").
The ADS ratio change is expected to become effective on or about January 14, 2025, U.S. Eastern Time (the "effective date"). Previously, Evaxion planned for the ADS ratio change to become effective on or about January 13, 2025. The date has been extended by one day as Nasdaq Capital Markets was closed on January 9, 2025, in order to observe the passing of President Jimmy Carter. This was not known when Evaxion announced the initial effective date.
For the company's ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split and is intended to further support the liquidity in the company's ADSs.

Stock Split

EVAX

Evaxion Announces Extension To January 14, 2025, Of Plan To Implement ADS Ratio Change From The Current One 1 ADS Representing 10 Ordinary Share To A New ADS Ratio Of 1 ADS Representing 50 Ordinary Shares

Publication reports 100% of participants were either "Much Improved" or "Very Much Improved" as rated by the Clinician Global Impression of Change following 12-weeks of QTORIN&#x2122; rapamycin
FDA previously granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation to QTORIN&#x2122; rapamycin for microcystic lymphatic malformations (microcystic LMs)
Ongoing Phase 3 single-arm, baseline-controlled trial evaluating QTORIN&#x2122; rapamycin for the treatment of microcystic LMs with topline data expected in Q1 2026
QTORIN&#x2122; rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs

Palvella Therapeutics Announces Publication Of Phase 2 Trial Results Of QTORIN 3.9% Rapamycin In Journal of Vascular Anomalies

Axogen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2024 key financials.
Preliminary Fourth Quarter and Year-End Key Business Highlights
<ul>
<li>Fourth quarter revenue is expected to be approximately $49.4 million, which represents a 15.1% increase over the fourth quarter of 2023 driven by solid performance across the product portfolio. &nbsp;</li>
<li>Full-year 2024 revenue is expected to be approximately $187.3 million, which represents a 17.8% increase over the full-year of 2023. &nbsp;</li>
<li>Our positive performance reflects continued improvements in the execution of our commercial strategies, including a focus on high-potential accounts in Extremities and OMF-Head &amp; Neck applications, adoption of Axogen's complete peripheral nerve surgical algorithm across all procedures, and continued adoption of Resensation&#xAE; as an expectation for post mastectomy breast reconstruction procedures. &nbsp;</li>
<li>We expect full year gross margin to be above 75.5%. &nbsp;</li>
<li>Total balance of cash, cash equivalents and investments on December 31, 2024, is expected to be approximately $39.5 million, representing an increase of approximately $2.5 million over that balance at the end of 2023.</li>
</ul>

Guidance

AXGN

Axogen Reports Preliminary Q4 Revenue $49.4M, Up 15.1% YoY; FY24 Revenue $187.3M, Up 17.8% YoY; Expect Full Year Gross Margin To Be Above 75.5%

JP Morgan analyst Rodolfo Angele upgrades YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) from Neutral to Overweight and raises the price target from $25 to $59.5.

Upgrades

JP Morgan Upgrades YPF to Overweight, Raises Price Target to $59.5

5x30 Path to growth and value creation
The company intends to achieve the following five objectives by 2030 ("5x30"):
<ul>
<li>Patients: More than three million patients treated per year</li>
<li>Product revenue: Double-digit compounded annual growth rate</li>
<li>Profitability: Five percentage point gross margin improvement over 2024</li>
<li>Pipeline: Clinical pipeline expansion with five novel programs in development</li>
<li>Partnerships: Establishing five partnerships including pipeline and commercial agreements</li>
</ul>

PCRX

Pacira Reports Prelim. 2024 Revenue Of $710M vs $675.0M YoY; Co. Sets 2030 Goals Including More Than 3M Patients Treated Yearly

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and raises the price target from $68 to $70.

HALO

HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $70

<ul>
<li>Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis</li>
<li>After alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in wet AMD, 4FRONT-1 and 4FRONT-2 trials on track to initiate in Q1 2025 and Q3 2025 respectively</li>
<li>Primary endpoint 52-week topline data for both 4FRONT-1 and 4FRONT-2 expected in H2 2027</li>
<li>Cash runway extended under updated operating plan; unaudited cash, cash equivalents and marketable securities of $506M as of December 31, 2024 expected to fund operations into 2028</li>
</ul>
EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>, 4DMT or the Company))), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a strategically focused pipeline, updated Phase 3 4FRONT program plans, initial 4FRONT guidance and resulting updated cash runway guidance.

FDMT

4DMT Extends Cash Runway To 2028 With $506M, Plans Phase 3 Trials For 4FRONT-1 & 4FRONT-2 In Wet AMD, Develops Early-Stage DME And CF, Explores Partnerships And Strategic Financing

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has been analyzed by 25 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Nike and provided 12-month price targets. The average target is $83.44, accompanied by a high estimate of $105.00 and a low estimate of $70.00. Observing a downward trend, the current average is 4.0% lower than the prior average price target of $86.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1736514153_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Nike among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jonathan Komp</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$75.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$74.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$80.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$97.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Krisztina Katai</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$82.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Cristina Fernandez</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$93.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$79.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$84.00</td>
<td>-</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$73.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Piral Dadhania</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nike. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nike compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Nike's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Nike's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NKE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nike analyst ratings.</a>
<h2>Unveiling the Story Behind Nike</h2>
Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
<h3>Financial Milestones: Nike's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Nike showcased positive performance, achieving a revenue growth rate of 6.6% as of 30 November, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.41%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nike's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Nike's ROA stands out, surpassing industry averages. With an impressive ROA of 3.07%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Nike's debt-to-equity ratio is below the industry average at 0.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Nike: 25 Analysts Share Their Views

Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $37.5, a high estimate of $40.00, and a low estimate of $34.00. This current average has increased by 4.17% from the previous average price target of $36.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1736514129_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Verint Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$34.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Dan Bergstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Joshua Reilly</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Verint Systems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Verint Systems compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Verint Systems's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Verint Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Verint Systems analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Verint Systems's Background</h2>
Verint Systems Inc with its subsidiaries helps brands provide Boundless Customer Engagement. The company's solutions help iconic brands close the gap created when it lacks the resources required to deliver experiences that fulfill customer expectations. Geographically, it derives a majority of its revenue from the United States.
<h3>A Deep Dive into Verint Systems's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Verint Systems showcased positive performance, achieving a revenue growth rate of 2.58% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.02%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Verint Systems's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.88%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Verint Systems's ROA stands out, surpassing industry averages. With an impressive ROA of 1.12%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Verint Systems's debt-to-equity ratio is below the industry average at 0.5, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRNT

Assessing Verint Systems: Insights From 4 Financial Analysts

Latest data shows the largest indicative borrow rate increases among liquid option names include: Endeavor Group Holdings (EDR) 16.10% +2.31, Sound...

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Equinor (EQNR) 8.09% +3.32, Workhorse Group (WKHS...

Latest data shows the largest indicative borrow rate increases among liquid option names include: GlycoMimetics (GLYC) 26.88% +2.41, Endeavor Group...

SNDL (SNDL) appointed Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. Phil McBride joins SNDL with...

SNDL appoints new Chief Information Officer and new President, Liquor Division

SNDL (SNDL) has released an update. SNDL Inc. has appointed Phil McBride as Chief Information Officer and Navroop Sandhawalia as President of its L...

Comments

SNDL

空売り

SNDL (NASDAQ:SNDL) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル